Literature DB >> 32181674

Autologous Chondrocyte Implantation as Treatment for Unsalvageable Osteochondritis Dissecans: 10- to 25-Year Follow-up.

James L Carey1, Kevin G Shea2, Anders Lindahl3, Haris S Vasiliadis4, Carl Lindahl3, Lars Peterson3.   

Abstract

BACKGROUND: An unsalvageable osteochondritis dissecans (OCD) fragment has been defined as one that cannot be saved. Unsalvageable OCD lesions have been treated with various techniques, including fragment excision, microfracture, osteochondral autograft transfer, fresh osteochondral allograft transplantation, and autologous chondrocyte implantation (ACI). HYPOTHESIS: Patients who underwent ACI as treatment for unsalvageable OCD more than 10 years ago would maintain satisfactory patient-oriented outcome measures and have a low need for additional open surgery, especially arthroplasty. STUDY
DESIGN: Case series; Level of evidence, 4.
METHODS: All Swedish and Norwegian patients (59 patients with 67 OCD lesions) who underwent ACI for OCD under the direction of the senior author between 1990 and 2005 were identified through manual chart review. Features of the patient, OCD lesion, and surgery were extracted from the medical record and intraoperative photographs. Patients were sent questionnaires to assess the Knee injury and Osteoarthritis Outcome Score, Tegner-Wallgren activity score, and Lysholm score. In addition, patients were asked whether they had to undergo further surgery, including knee replacement, of the knee that underwent ACI. They were asked whether they would have the surgery again if in the same situation.
RESULTS: A total of 55 patients (93%) with 61 OCD lesions (91%) responded. The median follow-up duration was 19 years (range, 10-26 years) and the median age at follow-up was 43 years (range, 28-69 years). Subsequent arthroscopy was performed in the majority of cases, although many of these were scheduled "second looks" as part of a study. With respect to other subsequent surgery, 12 knees (20%) underwent any additional open surgery, but only 2 knees (3%) underwent arthroplasty. Eight knees (13%) underwent revision ACI. Most patients reached their preinjury activity level (62%) and would undergo ACI again if in the same situation (85%). If failure is defined as revision of the graft or conversion to arthroplasty, then survivorship after ACI for OCD in the current study would be 87% at 10 years, 85% at 15 years, and 82% at 20 years.
CONCLUSION: ACI for OCD provides a durable treatment option. At a median follow-up of 19 years, there was a very low (~3%) conversion to total knee arthroplasty.

Entities:  

Keywords:  articular cartilage resurfacing; autologous chondrocyte implantation; knee; long-term outcomes; osteochondritis dissecans

Year:  2020        PMID: 32181674     DOI: 10.1177/0363546520908588

Source DB:  PubMed          Journal:  Am J Sports Med        ISSN: 0363-5465            Impact factor:   6.202


  11 in total

1.  Treatment of Juvenile Knee Osteochondritis Dissecans with a Cell-Free Biomimetic Osteochondral Scaffold: Clinical and MRI Results at Mid-Term Follow-up.

Authors:  Andrea Sessa; Iacopo Romandini; Luca Andriolo; Alessandro Di Martino; Maurizio Busacca; Stefano Zaffagnini; Giuseppe Filardo
Journal:  Cartilage       Date:  2020-09-10       Impact factor: 3.117

2.  Time Matters: Knee Cartilage Defect Expansion and High-Grade Lesion Formation while Awaiting Autologous Chondrocyte Implantation.

Authors:  Robert J Pettit; Joshua S Everhart; Alex C DiBartola; Ryan E Blackwell; David C Flanigan
Journal:  Cartilage       Date:  2021-12-11       Impact factor: 3.117

3.  Repairing Cartilage with Processed Chondrocyte Constructs: A 6-Month Study Using a Porcine Model.

Authors:  Akihiko Kusanagi; Eric B Blahut; Takahiro Ogura; Akihiro Tsuchiya; Shuichi Mizuno
Journal:  Cartilage       Date:  2021-11-11       Impact factor: 3.117

4.  Sustained superiority in KOOS subscores after matrix-associated chondrocyte implantation using spheroids compared to microfracture.

Authors:  Arnd Hoburg; Philipp Niemeyer; Volker Laute; Wolfgang Zinser; Christoph Becher; Thomas Kolombe; Jakob Fay; Stefan Pietsch; Tomasz Kuźma; Wojciech Widuchowski; Stefan Fickert
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2022-10-21       Impact factor: 4.114

5.  Fabrication and maturation of integrated biphasic anatomic mesenchymal stromal cell-laden composite scaffolds for osteochondral repair and joint resurfacing.

Authors:  George W Fryhofer; Hannah M Zlotnick; Brendan D Stoeckl; Megan J Farrell; David R Steinberg; Robert L Mauck
Journal:  J Orthop Res       Date:  2021-01-14       Impact factor: 3.494

Review 6.  Osteochondritis Dissecans: Current Understanding of Epidemiology, Etiology, Management, and Outcomes.

Authors:  Michael M Chau; Mikhail A Klimstra; Kelsey L Wise; Jutta M Ellermann; Ferenc Tóth; Cathy S Carlson; Bradley J Nelson; Marc A Tompkins
Journal:  J Bone Joint Surg Am       Date:  2021-06-16       Impact factor: 6.558

7.  Chondral and Osteochondritis Dissecans Lesions Treated by Autologous Chondrocytes Implantation: A Mid- to Long-Term Nonrandomized Comparison.

Authors:  Teemu Paatela; Anna Vasara; Markus Sormaala; Heikki Nurmi; Hannu Kautiainen; Ilkka Kiviranta
Journal:  Cartilage       Date:  2020-06-30       Impact factor: 3.117

8.  Biosafety evaluation of culture-expanded human chondrocytes with growth factor cocktail: a preclinical study.

Authors:  Maimonah-Eissa Al-Masawa; Wan Safwani Wan Kamarul Zaman; Kien-Hui Chua
Journal:  Sci Rep       Date:  2020-12-09       Impact factor: 4.379

9.  Osteochondral autograft transplantation versus autologous bone-cartilage paste grafting for the treatment of knee osteochondritis dissecans.

Authors:  Alessandro Di Martino; Simone Silva; Luca Andriolo; Giulia Merli; Davide Reale; Stefano Zaffagnini; Giuseppe Filardo
Journal:  Int Orthop       Date:  2020-09-21       Impact factor: 3.075

10.  Osteochondritis dissecans of the glenoid: an analysis of grades, treatment, and outcomes.

Authors:  Dinshaw N Pardiwala; Kushalappa Subbiah; Nandan Rao
Journal:  JSES Int       Date:  2021-04-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.